Novartis ($NVS) was last year's biggest R&D spender in the pharma industry. Now, the company is warning U.K. officials that, unless they change their ways, Novartis will be spending less and less of its research billions in that country. Report
| Thursday, February 19th | 10am ET / 7am PT / 4pm CET / 3pm GMT | Sponsored by: Elsevier
This webinar will bring together pharmaceutical executives across a range of functions—from marketing to regulatory affairs to development—to discuss these trends and suggest strategies for thriving in this increasingly vigilant environment. Register Now!
FiercePharma is the pharma industry's daily monitor, with a special focus on pharmaceutical company news and the market development of FDA approved products. Join 150,000+ pharma industry leaders who get FiercePharma via daily email. Click here to get your free weekly email briefing today!